Los puntos clave no están disponibles para este artículo en este momento.
overexpression was associated with poor prognosis. In summary, KPT-330 with AZA exerted synergistic effects by suppressing XPO1/eIF4E/c-MYC signaling, which provided preclinical evidence for further clinical application of the novel combination in AML.
Long et al. (Thu,) studied this question.